The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Exact Sciences; Lilly; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Novartis; Roche
Speakers' Bureau - AstraZeneca; Novartis; Roche
Research Funding - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Novartis; Pfizer; Roche
Relationship of adaptive subtyping and tumour heterogeneity of treatment response to neoadjuvant therapy in hormone receptor–positive HER2-negative early breast cancer: PENELOPE-B.
 
Carsten Denkert
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; MSD Oncology
Research Funding - German Breast Group (Inst); Myriad Genetics (Inst)
Patents, Royalties, Other Intellectual Property - Patent WO2010076322A1; Patent WO2015114146A1; Patent WO2020109570A1; VMScope digital pathology software
 
Krishna Rachakonda
No Relationships to Disclose
 
Martin Filipits
Honoraria - AstraZeneca; Bio-Rad; Boehringer Ingelheim; Lilly; Merck; Novartis
 
Karsten Weber
No Relationships to Disclose
 
Frederik Marmé
No Relationships to Disclose
 
Michael Untch
Honoraria - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca; AstraZeneca (Inst); Baxter (Inst); Daiji Sankyo (Inst); Eisai Europe (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst)
Consulting or Advisory Role - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Medac (Inst); MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi Aventis GmbH (Inst); Stemline Therapeutics
 
Agnieszka K Witkiewicz
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
 
Angela DeMichele
Consulting or Advisory Role - Pfizer (I)
Research Funding - Genentech (Inst); Inivata/NeoGenomics (Inst); Novartis (Inst); Pfizer (Inst)
 
Anika Pehl
No Relationships to Disclose
 
Laura van 't Veer
Employment - Agendia
Stock and Other Ownership Interests - Agendia; Exai Bio
 
Paul Jank
No Relationships to Disclose
 
Christian Schem
No Relationships to Disclose
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche
 
Toralf Reimer
No Relationships to Disclose
 
Erik S. Knudsen
Research Funding - Blueprint Medicines; Bristol-Myers Squibb
 
Yuan Liu
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Federico Gustavo Rojo Todo
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Menarini; Merck; MSD; Novartis; Roche
Research Funding - AstraZeneca; Menarini
 
Nicholas C. Turner
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Guardant Health; Inivata; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Relay Therapeutics; Repare Therapeutics; Roche
Research Funding - AstraZeneca (Inst); Guardant Health (Inst); Inivata (Inst); InVitae (Inst); Merck Sharpe and Dohme (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst); Roche (Inst)
 
Sibylle Loibl
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Menarini Group (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Speakers' Bureau - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Menarini Group (Inst); MolecularHealth (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Digital Ki67 Evaluator, VM Scope GmbH (Inst); Patent Issued EP15702464.7 (Inst); Patent Pending EP14153692.0 (Inst); Patent Pending EP19808852.8 (Inst); Patent Pending EP21152186.9 (Inst)